Related Experiment Video

Updated: May 28, 2026

A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Angiogenesis and melanoma - from basic science to clinical trials

Maxine Sylvia Emmett, Daemon Dewing, Rowan Oliver Pritchard-Jones

    American Journal of Cancer Research
    |October 22, 2011
    PubMed

    Insights

    Anti-angiogenic therapies, targeting Vascular Endothelial Growth Factor (VEGF), offer new hope for metastatic malignant melanoma. While not yet revolutionary, ongoing trials explore their potential to improve outcomes and prevent metastasis.

    Area of Science:

    • Oncology
    • Medical research

    Background:

    • Malignant melanoma management traditionally relies on surgery, chemotherapy, and radiotherapy.
    • Anti-angiogenic agents represent a significant advancement, offering a fourth therapeutic modality.
    • Vascular Endothelial Growth Factor (VEGF) is a key target in developing these novel therapies.

    Purpose of the Study:

    • To review the current status and rationale of clinical trials involving anti-angiogenic therapies for metastatic malignant melanoma.
    • To assess the outcomes of key clinical trials and understand their impact on melanoma care.
    • To explore future directions for optimizing anti-angiogenic therapy in melanoma treatment.

    Main Methods:

    • Review of preclinical studies demonstrating the efficacy of anti-angiogenic agents.
    • Analysis of clinical trial data for anti-angiogenic therapies in metastatic melanoma.
    • Examination of combination therapies involving anti-VEGF agents and established treatments.

    Main Results:

    • Preclinical research generated significant enthusiasm for anti-angiogenic agents.
    • Clinical trials combining anti-VEGF therapies with other treatments show some promise for metastatic melanoma.
    • Current anti-angiogenic therapies have not yet revolutionized melanoma care as anticipated.

    Conclusions:

    • Anti-angiogenic therapies, particularly targeting VEGF, hold potential in managing metastatic malignant melanoma.
    • Further research and optimized targeting strategies are necessary to enhance the efficacy of these agents.
    • Combination therapies and trials aimed at metastasis prevention are crucial for future advancements.
    Keywords:
    CancerVEGFangiogenesisanti-angiogenic therapybevacizumabmelanomametastatic melanomareceptor tyrosine kinase inhibitorssignal transduction inhibitorsvascular endothelial growth factor

    More Related Videos

    A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

    A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

    Published on: March 8, 2022

    Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

    Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

    Published on: November 23, 2014

    Related Concept Videos

    Mechanism of Angiogenesis01:10

    Mechanism of Angiogenesis

    Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
    Regulation of Angiogenesis and Blood Supply01:24

    Regulation of Angiogenesis and Blood Supply

    Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
    Cancer Therapies02:49

    Cancer Therapies

    Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
    However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...